Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | EDNRB | P24530 | 2/20 | 0.44 |
| ▸ | EDNRA | P25101 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038954 | 0.87 | KMT2A (0.50) | MEN1KMT2ACCR2HTTLMNA | |
| SCHEMBL6038416 | 0.87 | TSHR (0.51) | MEN1KMT2ACCR2EDNRBEDNRA | |
| SCHEMBL6038515 | 0.85 | KMT2A (0.49) | MEN1KMT2ACCR2HTTEDNRB | |
| SCHEMBL6039126 | 0.85 | AR (0.50) | MEN1KMT2ACCR2HTTEDNRB | |
| SCHEMBL6039220 | 0.85 | MEN1 (0.53) | MEN1KMT2ACCR2EDNRBEDNRA | |
| SCHEMBL6038740 | 0.84 | KDM4E (0.61) | MEN1KMT2AEDNRBEDNRARXFP1 | |
| SCHEMBL6038452 | 0.83 | MEN1 (0.46) | MEN1KMT2ACCR2HTTEDNRB | |
| SCHEMBL6039048 | 0.81 | MEN1 (0.49) | MEN1KMT2ACCR2HTTEDNRB | |
| SCHEMBL6038427 | 0.81 | MEN1 (0.46) | MEN1KMT2ACCR2EDNRBEDNRA | |
| SCHEMBL6038879 | 0.79 | KMT2A (0.52) | MEN1KMT2ACCR2HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | MEN1 2431/4885KMT2A 4190/4885CCR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.